NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $4,417 | $55,333 | $77,882 | $87,368 |
| % Growth | -92% | -29% | -10.9% | – |
| Cost of Goods Sold | $2,221 | $5,984 | $7,899 | $163,972 |
| Gross Profit | $2,196 | $49,349 | $69,983 | -$76,604 |
| % Margin | 49.7% | 89.2% | 89.9% | -87.7% |
| R&D Expenses | $112,008 | $181,067 | $161,712 | $163,972 |
| G&A Expenses | $37,840 | $40,515 | $36,865 | $27,229 |
| SG&A Expenses | $36,735 | $40,515 | $36,865 | $27,229 |
| Sales & Mktg Exp. | -$1,105 | $0 | $0 | $0 |
| Other Operating Expenses | -$234 | -$132 | -$60 | -$593 |
| Operating Expenses | $148,743 | $221,582 | $198,577 | $191,201 |
| Operating Income | -$146,547 | -$166,249 | -$120,695 | -$103,833 |
| % Margin | -3,317.8% | -300.5% | -155% | -118.8% |
| Other Income/Exp. Net | $4,172 | $3,582 | $360 | $1,346 |
| Pre-Tax Income | -$142,375 | -$162,667 | -$120,335 | -$102,487 |
| Tax Expense | $0 | -$3,582 | -$6,509 | -$8,494 |
| Net Income | -$142,375 | -$159,085 | -$113,826 | -$93,993 |
| % Margin | -3,223.3% | -287.5% | -146.2% | -107.6% |
| EPS | -1.73 | -1.99 | -1.48 | -1.37 |
| % Growth | 13.1% | -34.5% | -8% | – |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 |
| Weighted Avg Shares Out | 82,496 | 79,950 | 77,085 | 68,475 |
| Weighted Avg Shares Out Dil | 82,496 | 79,950 | 77,085 | 68,475 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,322 | $3,714 | $420 | $1,939 |
| Interest Expense | $0 | $3,714 | $0 | $0 |
| Depreciation & Amortization | $2,221 | $4,035 | $6,089 | $6,555 |
| EBITDA | -$144,326 | -$154,918 | -$120,695 | -$103,833 |
| % Margin | -3,267.5% | -280% | -155% | -118.8% |